A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo

Trial Profile

A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo

Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Oct 2014

At a glance

  • Drugs Auriclosene (Primary)
  • Indications Impetigo; Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors NovaBay Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2013 Galderma expects to complete enrolment in the third quarter of 2013, and top-line results are expected in the fourth quarter of 2013, according to a NovaBay Pharmaceuticals media release.
    • 05 Feb 2013 Enrollment has been initiated in the South African arm of this trial, according to a NovaBay Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top